Loading...
Loading...
Browse all stories on DeepNewz
VisitJAMA Internal Medicine Study: Mounjaro Leads to Greater Weight Loss Than Ozempic
Jul 8, 2024, 04:00 PM
A new study published in JAMA Internal Medicine has found that Eli Lilly's Mounjaro (tirzepatide) leads to significantly greater weight loss compared to Novo Nordisk's Ozempic (semaglutide). The study, which involved 20,000 participants, used real-world data and matched propensity analysis to compare the effectiveness of the two drugs. Results indicate that patients taking Mounjaro lost more weight than those on Ozempic, and the longer the treatment duration, the wider the gap in weight loss between the two groups. Additionally, tirzepatide, the active ingredient in Mounjaro, also outperformed semaglutide in Wegovy and Zepbound.
View original story
Markets
No • 50%
Yes • 50%
Novo Nordisk official announcements and press releases
Yes • 50%
No • 50%
FDA official announcements and website
Ozempic > 60% • 25%
Mounjaro > 60% • 25%
Mounjaro 40-60% • 25%
Ozempic 40-60% • 25%
Market research reports and pharmaceutical sales data
Eli Lilly > 20% increase • 25%
Novo Nordisk > 20% increase • 25%
Novo Nordisk 10-20% increase • 25%
Eli Lilly 10-20% increase • 25%
Official stock market data and financial news outlets
Mounjaro > 10% more effective • 25%
Mounjaro 5-10% more effective • 25%
Ozempic 5-10% more effective • 25%
Ozempic > 10% more effective • 25%
Published study results and medical journals